永太科技(002326.SZ):加巴噴丁原料藥車間項目已進入試生產階段
格隆匯 12 月 28日丨永太科技(002326.SZ)公佈,近日,公司全資子公司浙江永太手心醫藥科技有限公司(“永太手心”)年產4340噸原料藥、6億粒中藥提取建設項目部分車間已完成設備安裝調試工作,其中年產1800噸的加巴噴丁原料藥車間項目試生產方案經專家評審通過,於近日正式進入試生產階段。
該原料藥車間項目的投產標誌着該項目開始進入產能釋放期,有利於公司擴大現有醫藥原料藥產能規模,與公司另一個子公司浙江手心製藥有限公司(“浙江手心”)共同構成了公司醫藥原料藥的主要生產平台,強化了公司在醫藥產業的競爭力,符合公司的發展戰略。此次投產的加巴噴丁產品是公司醫藥板塊首個實現“原料藥+製劑”的產品鏈,其中加巴噴丁原料藥由浙江手心和永太手心生產,加巴噴丁膠囊製劑由公司另一子公司浙江永太藥業有限公司生產。在該模式下,進一步提升了公司產品的成本優勢、一體化產業鏈供應優勢,增強了公司綜合競爭力及盈利能力。該項目的投產運營將對公司未來的發展產生一定的積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.